4th UpDate on Hepatology

Similar documents
PRELIMINARY SCIENTIFIC PROGRAM :50 Meet the experts- Molecular mechanisms in IBD from basic science to therapy. Franco-Romanian Meeting

6 th UpDate. on Hepatology Course Bucharest Romania 2019 Title: From theory to practice in liver disease

SCIENTIFIC PROGRAM. The First Franco-Romanian Meeting

PROGRAMME AT A GLANCE

The 10th National Symposium on Inflammatory Bowel Diseases

Dear Colleagues and Friends of the pancreas,

SCIENTIFIC PROGRAM Pharma Symposium Takeda: Changing the Game in IBD. Speakers: Bogdan Mateescu, Lucian Negreanu

Tumor incidence varies significantly, depending on geographical location.

Dear colleagues and friends,

Angelos Hatzakis. 10th Paris Hepatology Conference

Liver transplantation: an ongoing challenge

From Medical Treatment to Liver Transplantation PROGRAM NAFLD/NASH CONSENSUS CONFERENCE 2018

RCCC Romanian Crohn`s

Surveillance for Hepatocellular Carcinoma

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice

International Society of Microbiota

Hepatocellular Carcinoma. Markus Heim Basel

HIV and HCV coinfection - Barriers in Central and Eastern Europe

Liver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York

Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC

THE ROMANIAN HEPATITIS ACTION PAPER

Hepatocellular Carcinoma (HCC)

P R O G R A M. 08:50 09:10 Present and future of surgery of pancreatic cancer: how far can we go?

KIDNEY LIVER MEETS FINAL PROGRAM KIDNEY MEETS LIVER. When the excellence in renal and liver medicine come together. XXXXXXX

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health

Hepatocellular carcinoma

Progression of the disease. Heiner Wedemeyer

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

RJGE VOL.12, NR.2, JUNE 2003

Hepatology For The Nonhepatologist

EASL HCC SUMMIT 2018 FROM BASIC TO CLINICAL RESEARCH: HOW TO IMPROVE HCC CLINICAL CARE? 01 03, MARCH 2018 GENEVA, SWITZERLAND

DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC.

Liver transplant: what is left after the viruses

Hepatology for the Nonhepatologist

1 ST EUROPEAN. NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT.

Dynamics of the Romanian Waiting List for Liver Transplantation after Changing Organ Allocation Policy

Programme September 2017 Prague, Czech Republic

RJGE VOL.11, NR.1, MARCH 2002

HCV elimination : lessons from Scotland

Liver resection for HCC

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Pretreatment Evaluation

Autoimmune Hepatitis Events Easl

Liver disease in 2017: challenges and opportunities

15 & 16 January International Conference on the Management of Liver Diseases. Organised by Pr Patrick Marcellin

Viral hepatitis and Hepatocellular Carcinoma

Screening for Portal Hypertension in Cirrhosis

Combined EFISDS & EDS Postgraduate Course 2014 October 30 th November 1 st 2014, Cluj-Napoca, Romania Challenges in GI-Surgery. Scientific Program

Pretreatment Evaluation

HCC and the Hallmarks of Cancer: steps towards novel therapeutic strategies

WORLDWIDE EPIDEMIOLOGY OF NASH

Hepatitis C in Disclosures

HCV care after cure. This program is supported by educational grants from

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Hepatocellular Carcinoma: Diagnosis and Management

Original papers Med Ultrason 2013, Vol. 15, no. 2, Ioan Sporea, Iulia Raţiu, Simona Bota, Roxana Şirli, Ana Jurchiş

SCIENTIFIC PROGRAMME

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

Disease Burden of Non Alcoholic Fatty Liver Disease (NAFLD)

Antiviral Therapy and Liver Cancer

Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010

New York State HCV Provider Webinar Series. Side Effects of Therapy

Hepatitis C Policy Discussion

Organized by. Scientific comittee


Professor Norbert Bräu

Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus / Fax

47 th Annual Meeting AISF

Life After SVR for Cirrhotic HCV

Hepatitis C - results in real life

Saturday, 5 December 2015 Ramada Parc Hotel, Conference Hall 1

Supplementary Digital Content

Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co infection

Seminars ELECTRONEUROMYOGRAPHY SEMINAR MODULE 12 IN CONJUNCTION WITH

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

LIVER DISEASE IN RESOURCE LIMITED SETTINGS

9th Paris Hepatitis Conference

HEPATITIS B: WHO AND WHEN TO TREAT?

Volume 26 Supplement

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

The future of liver transplantation for viral hepatitis

The Impact of HBV Therapy on Fibrosis and Cirrhosis

Transplant Hepatology

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

RATIONALE FOR INCLUSION IN PA PROGRAM

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

EULIS - PNL WORKSHOP 1-3 November 2018 Timisoara, Romania Programme

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT

International Hepatitis Symposium Heidelberg

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

Organized by: Division of Hepatology and Gene Therapy

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.

Transcription:

4th UpDate on Hepatology Course Bucharest 2017, Romania 6 th - 7 th April 2017 Bucharest - Crowne Plaza Hotel Hepatology 2017 A panoramic view" Liana GHEORGHE Course Directors Ioan SPOREA Anca TRIFAN

4 th UpDate on Hepatology Course, Bucharest 6 th -7 th April 2017 Hepatology 2017 A panoramic view" 6 April 2017 8.00-9.45 Registration & Welcome 9.50-10.00 Introduction: Liana Gheorghe 10.00-11.30 Challenging issues in hepatitis B Chair: Pietro Lampertico, Mircea Diculescu 10.00-10.25 How to manage HBV infected patients in 2017? Pietro Lampertico, Milan, Italy 10.25-10.45 Hepatitis B reactivation prevention and therapy Adrian Goldiş, Timişoara, România 10.45-11.05 Long-term impact of antiviral therapy in chronic hepatitis B Marcel Tanţău, Cluj-Napoca, România 11.05-11.30 Recent advances in HDV therapy Jerzy Jaroszewicz, Bialystok, Poland 11.30-13.00 Alcoholic and non-alcoholic liver disease Chair: Vlad Ratziu 11.30-11.50 Old and new biomarkers for NASH Mona Munteanu, Paris, France 11.50-12.15 The impact of new multi-parametric measures of fatty liver by ultrasound and magnetic resonance in clinical practice Ferrucio Bonino, Pisa, Italy 12.15-12.35 What is the current medical management of NASH and future perspectives Ioan Sporea, Timişoara, România 12.35-13.00 Treatment of alcoholic hepatitis Vlad Ratziu, Paris, France 13.00-13.30 Satellite Symposium BMS Speaker: Pietro Lampertico, Milan, Italy 13.30-14.30 Lunch

14.30-16.00 Challenging issues in hepatitis C Chair: Nancy Reau, Ioan Sporea 14.30-14.50 HCV treatment of GT-1 patients now and in the future. Strategies for simplification Liana Gheorghe, Bucharest, România 14.50-15.15 Treatment of HCV special populations: decompensated cirrhosis and chronic kidney disease Susanne Beckebaum, Muenster, Germany 15.15-15.40 Impact of therapy on hepatic and extrahepatic manifestation of chronic HCV infection Nancy Reau, Chicago, USA 15.40-16.00 Hepatocellular carcinoma in patients with HCV liver cirrhosis treated with direct-acting antivirals (DAAs) Speranţa Iacob, Bucharest, România 16.00-16.30 Coffee Break and Poster Viewing 16.30-17.30 Satellite Symposium AbbVie 17.30-18.30 Parallel Case-based Workshops 1. Susanne Beckebaum, Speranţa Iacob: Management of chronic hepatitis C 2. Cristian Gheorghe, Carol Stanciu: Special issues in liver cirrhosis 3. Ioan Sporea, Vlad Ratziu: Alcoholic & non-alcoholic fatty liver disease 18.30 Dinner 7 April 2017 8.30-10.30 Hepatocellular carcinoma Chair: Patrizia Burra 8.30-8.50 Combination and dynamics of serum biomarkers to personalized surveillance, diagnosis and management of hepatocellular carcinoma Maurizia Brunetto, Pisa, Italy 8.50-9.10 Diagnosis of hepatocellular carcinoma by imaging : How can we improve accuracy? Ioana Lupescu, Bucharest, România 9.10-9.30 Radiofrequency ablation: who should be treated, how to be done and response evaluation Zeno Spârchez, Cluj-Napoca, România

q 9.30-9.50 Transarterial chemoembolization: who should be treated, how to be done and response evaluation Mugur Grasu, Bucharest, România 9.50-10.10 Transplantation for hepatocellular carcinoma Patrizia Burra, Padova, Italy 10.10-10.30 Systemic therapy and immunotherapy for advanced hepatocellular carcinoma Markus Peck-Radosavljevic, Austria 10.30-11.00 Coffee Break and Poster Viewing 11.00-12.00 Special issues in cirrhosis Chair: Vito Cicinnati, Cristian Gheorghe 11.00-11.20 Acute on chronic liver disease Anca Trifan, Iaşi, România 11.20-11.40 Use of betablockers in decompensated cirrhosis Cristina Cijevschi, Cătălina Mihai, Iaşi, România 11.40-12.00 Cirrhotic coagulopathy: practical aspects Dana Tomescu, Bucharest, România 12.00-13.00 q Satellite Symposium MSD 13.00-14.00 Lunch q 14.00-15.00 Satellite Symposium Gilead 15.00-16.30 Original Research Forum Chair: Costică Aloman, Răzvan Iacob 15.00-15.20 Arguments for hepatocyte reprogramming during advanced liver fibrosis background for hepatocarcinogenesis Răzvan Iacob, Bucharest, România 15.20-15.40 Targeting mononuclear phagocytes development in alcoholic liver injury: pathological and immunological pathways Costică Aloman, Chicago, USA 15.40-15.55 The metabolic profile of decompensation in patients with cirrhosis Bogdan Procopeţ, Cluj-Napoca, România

15.55-16.10 The role of combined liver and spleen elastometry for the prediction of the response to therapy in severe alcoholic hepatitis Horia Ştefănescu, Cluj-Napoca, România 16.10-16.30 Early-TIPS improves survival in high-risk variceal bleeders Results of a multicenter variceal bleeding observational study Virginia Hernandez Gea, Barcelona, Spain 16.30-17.00 Coffee Break q 17.00-17.30 Satellite Symposium Alfa Wassermann Gut Dysbiosis and Inflammation in Cirrhosis and Hepatic Encephalopathy: Role for Microbiota-directed Therapies Speaker: Carmelo Scarpignato, Parma, Italy 17.30-18.30 Autoimmune and genetic liver disease Chair: Susanne Beckebaum, Carol Stanciu 17.30-17.50 Management of autoimmune liver disease in 2017 Vito Cicinnati, Muenster, Germany 17.50-18.10 Management of cholestatic liver diseases in 2017 Iulia Simionov, Bucharest, România 18.10-18.30 Wilson disease: from genetics to therapy Hartmut Schmidt, Muenster, Germany 18.30 Closing and Poster Awards